Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 94   

Articles published

ALKS 62.26 -1.19 (-1.88%)
price chart
Alkermes Plc CMO Elliot Ehrich Sells 25000 Shares (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) CMO Elliot Ehrich sold 25,000 shares of the stock in a transaction dated Tuesday, April 21st.
Alkermes Plc insider Sells $1125900.00 in Stock (ALKS)  Mideast Time
Alkermes Plc (ALKS) Downgraded From Hold to Sell
"We rate ALKERMES PLC (ALKS) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover.
Insider Selling: Alkermes Plc COO Sells $1070850.00 in Stock (ALKS)  The Legacy
Alkermes Plc Downgraded by TheStreet to "Sell" (ALKS)  Intercooler
Alkermes Plc To Sell Georgia Facility To Recro Pharma; Recro Shares Soar 35%
Alkermes Plc (NASDAQ:ALKS), a biopharmaceutical company focusing on central nervous system diseases, announced Monday its plans to divest its Gainesville, Georgia manufacturing facility.
Jefferies Group Trims Alkermes Plc Target Price to $78.00 (ALKS)  Intercooler
Alkermes plc (NASDAQ:ALKS) Signed Into A Definitive Contract To Sell Its ...  StreetWise Report
Alkermes - The Underappreciated Biopharmaceutical (ALKS)
Alkermes Plc (NASDAQ:ALKS), an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas.
Alkermes Plc Receives $69.56 Consensus PT from Analysts (NASDAQ:ALKS)  Dakota Financial News
Citigroup Rating Update on Alkermes plc (NASDAQ:ALKS)  Trade Journo
Insider Selling: Alkermes Plc COO Sells $869137.50 in Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) COO Gordon G. Pugh sold 13,750 shares of Alkermes Plc stock on the open market in a transaction dated Wednesday, April 15th.
Alkermes Plc (NASDAQ:ALKS)'s SVP - COO & CRO - Alkermes - Inc ...  OctaFinance.com
Insider Selling: James M. Frates Sells 10000 Shares of Alkermes Plc Stock (ALKS)  Dakota Financial News
Alkermes plc (ALKS) Issues Positive Update on ALKS 3831 Phase 2 as ...
Alkermes plc (NASDAQ: ALKS) announced positive topline results from the complete, six-month, randomized, dose-ranging phase 2 study of ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum ...
Investment Seeking Stocks- Alkermes plc (NASDAQ:ALKS), Ventas, Inc. (NYSE ...  StreetWise Report
Alkermes Announces Positive Topline Results from Complete Six-Month Phase ...  MarketWatch
Is Alkermes plc Stock Undervalued?
In simple terms, what Alkermes plc (NASDAQ: ALKS ) is attempting to do is not easy. Few companies manage to successfully transition from being a licensor of drug formulation technologies to a proprietary drug developer and likewise few independent ...
Form 8-K Alkermes plc. For: Apr 10
On April 10, 2015, Alkermes Pharma Ireland Limited (�APIL�) and Eagle Holdings USA, Inc. (�Eagle,� and together with APIL, the �Sellers�), both indirect wholly-owned subsidiaries of Alkermes plc (the �Company�), completed the sale of a manufacturing ...
Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP ...  Nasdaq
Alkermes plc (ALKS) Phase 1 Study of ALKS 7106 Fails, Further Development ...
Alkermes plc (NASDAQ: ALKS) today announced topline results from a phase 1 clinical study of ALKS 7106, a new molecule intended for the treatment of pain.
Alkermes Plc (ALKS) Discontinues Development Of Pain Treatment; Stock Drops  Bidness ETC
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2014 and ...  Business Wire (press release)
Earnings of $-0.21 Expected in Q1 for Alkermes plc (NASDAQ:ALKS)
Sell-side Wall Street analysts are anticipating Alkermes plc (NASDAQ:ALKS) will post a current quarter earnings per share of $-0.21.